Kirsten Lindner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kirsten Lindner has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Richard Hummel
Department of General and Visceral Surgery; Muenster University Hospital; Muenster Germany
5 shared publicationsNorbert Senninger
4 shared publicationsDaniel Palmes
Department of General and Visceral Surgery; Muenster University Hospital; Muenster Germany
3 shared publicationsChristina Haane
Department of General and Visceral Surgery Muenster University Hospital Waldeyerstr. 1 48149 Muenster Germany
2 shared publications- Heiner Wolters
Department of General and Visceral Surgery, University Hospital Münster, Münster, Germany
2 shared publications - Jörg Haier
Comprehensive Cancer Center M-V, University Medicine Rostock, Rostock, Germany
2 shared publications
Latest Publications
- 1 August 2016
- Vol. 14 (4) , 419-23
Cytomegalovirus Treatment Strategy After a Liver Transplant: Preemptive Therapy or Prophylaxis for Cytomegalovirus Seropositive Donor and Recipient.
Cytomegalovirus infections cause the most frequent infection after solid-organ transplant. While Cytomegalovirus prophylaxis is established in high-risk patients (donor+/ recipient-), data on Cytomegalovirus prophylaxis in other serostatus constellation are rare. The aim of this study was to evaluate the influence of Cytomegalovirus treatment strategy after a liver transplant (preemptive therapy vs general prophylaxis) in the largest group of patients: Cytomegalovirus seropositive donor and recipient. Forty-seven seropositive recipients of seropositive donor liver transplants (D+/R+, 2005-2012) were included in this retrospective study. Twenty-one patients received oral valganciclovir as Cytomegalovirus prophylaxis 100 days after transplant. Cytomegalovirus infection and Cytomegalovirus disease were monitored during the first 6 months. A Cytomegalovirus infection could be detected in 4 out of 47 patients (8.5%), including Cytomegalovirus disease in 2 patients (Cytomegalovirus pneumonia and Cytomegalovirus-CNS disease). Three of these patients received no Cytomegalovirus prophylaxis (P = .408). Eight patients developed a graft failure; this occurred more frequently among patients without Cytomegalovirus prophylaxis (P = .044). Patients receiving Cytomegalovirus prophylaxis more often developed leukopenia. No difference was seen regarding the number of platelets, hemoglobin, and creatinine. Cytomegalovirus prophylaxis can minimize the risk of Cytomegalovirus reactivation and graft failure. However, disadvantages of the prophylaxis as leukopenia should be considered.
- 1 August 2016
- Vol. 14 (4) , 419-23
Cytomegalovirus Treatment Strategy After a Liver Transplant: Preemptive Therapy or Prophylaxis for Cytomegalovirus Seropositive Donor and Recipient.
Cytomegalovirus infections cause the most frequent infection after solid-organ transplant. While Cytomegalovirus prophylaxis is established in high-risk patients (donor+/ recipient-), data on Cytomegalovirus prophylaxis in other serostatus constellation are rare. The aim of this study was to evaluate the influence of Cytomegalovirus treatment strategy after a liver transplant (preemptive therapy vs general prophylaxis) in the largest group of patients: Cytomegalovirus seropositive donor and recipient. Forty-seven seropositive recipients of seropositive donor liver transplants (D+/R+, 2005-2012) were included in this retrospective study. Twenty-one patients received oral valganciclovir as Cytomegalovirus prophylaxis 100 days after transplant. Cytomegalovirus infection and Cytomegalovirus disease were monitored during the first 6 months. A Cytomegalovirus infection could be detected in 4 out of 47 patients (8.5%), including Cytomegalovirus disease in 2 patients (Cytomegalovirus pneumonia and Cytomegalovirus-CNS disease). Three of these patients received no Cytomegalovirus prophylaxis (P = .408). Eight patients developed a graft failure; this occurred more frequently among patients without Cytomegalovirus prophylaxis (P = .044). Patients receiving Cytomegalovirus prophylaxis more often developed leukopenia. No difference was seen regarding the number of platelets, hemoglobin, and creatinine. Cytomegalovirus prophylaxis can minimize the risk of Cytomegalovirus reactivation and graft failure. However, disadvantages of the prophylaxis as leukopenia should be considered.
- 1 March 2016
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
Potential risk factors and outcomes of fistulas between the upper intestinal tract and the airway following Ivor-Lewis esophagectomy
Fistulas between the upper intestinal tract and the airway following esophagectomy are a rare and severe complication with significant mortality. Treatment and therapy are difficult and require a multidisciplinary approach. The objective of this retrospective study was to identify risk factors for these fistulas following esophagetcomy, and to assess their impact on the further clinical course and outcome. 211 patients undergoing Ivor-Lewis esophagectomy for esophageal cancer between 2005 and 2012 were included. The preoperative risk factors including the risk score according to Schröder et al. and the O-Physiological and Operative Severity Score (POSSUM) score, operative and postoperative parameters and the outcome were evaluated. 65% of all patients developed postoperative complications, including 12 patients that developed fistulas between the upper intestinal tract and the airway (airway fistulas [AF]; 5.6%). Neither patient related risk factors nor esophagus-specific risk scores correlated with occurrence of AF. Furthermore, surgical treatment and neoadjuvant treatment did not show any effect on development of AF in our patients. However, we could demonstrate that AF significantly impacted on length of hospital stay (AF 52 days vs. No-AF group 16 days, P<0.001), incidence of major pulmonary complications (83.3% vs. 17.1%, P<0.001), 90-day mortality (42% vs. 7.5%, P=0.002) and overall survival (133 days vs. 636 days, P=0.029). With the current study, we could not identify any patient related risk factors, esophagus-specific risk scores or treatment related details that might be useful as predictors of AF after Ivor-Lewis esophagectomy. However, we confirmed that AF significantly impacted on outcomes. This highlights the urgent need for further studies on this rare but devastating complication after esophagectomy.
- 1 March 2016
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
Potential risk factors and outcomes of fistulas between the upper intestinal tract and the airway following Ivor-Lewis esophagectomy
Fistulas between the upper intestinal tract and the airway following esophagectomy are a rare and severe complication with significant mortality. Treatment and therapy are difficult and require a multidisciplinary approach. The objective of this retrospective study was to identify risk factors for these fistulas following esophagetcomy, and to assess their impact on the further clinical course and outcome. 211 patients undergoing Ivor-Lewis esophagectomy for esophageal cancer between 2005 and 2012 were included. The preoperative risk factors including the risk score according to Schröder et al. and the O-Physiological and Operative Severity Score (POSSUM) score, operative and postoperative parameters and the outcome were evaluated. 65% of all patients developed postoperative complications, including 12 patients that developed fistulas between the upper intestinal tract and the airway (airway fistulas [AF]; 5.6%). Neither patient related risk factors nor esophagus-specific risk scores correlated with occurrence of AF. Furthermore, surgical treatment and neoadjuvant treatment did not show any effect on development of AF in our patients. However, we could demonstrate that AF significantly impacted on length of hospital stay (AF 52 days vs. No-AF group 16 days, P<0.001), incidence of major pulmonary complications (83.3% vs. 17.1%, P<0.001), 90-day mortality (42% vs. 7.5%, P=0.002) and overall survival (133 days vs. 636 days, P=0.029). With the current study, we could not identify any patient related risk factors, esophagus-specific risk scores or treatment related details that might be useful as predictors of AF after Ivor-Lewis esophagectomy. However, we confirmed that AF significantly impacted on outcomes. This highlights the urgent need for further studies on this rare but devastating complication after esophagectomy.
- 1 January 2016
- Vol. 62 (1)
Procalcitonin--a Marker for Anastomotic Insufficiency after Pancreatoduodenectomy?
- 1 January 2016
- Vol. 62 (1)
Procalcitonin--a Marker for Anastomotic Insufficiency after Pancreatoduodenectomy?
- 8 February 2015
- Published by Springer Nature in Der Chirurg
- Vol. 86 (9) , 874-880
Therapiepause in der multimodalen Behandlung des Ösophaguskarzinoms
Die neoadjuvante (Radio-)Chemotherapie [n(R)CT] ist fester Bestandteil des multimodalen Therapiekonzepts beim fortgeschrittenen Ösophaguskarzinom, wobei der optimale Operationszeitpunkt nach komplettierter n(R)CT nicht eindeutig definiert ist. Die Studie untersucht die Auswirkung der Therapiepause, definiert als Intervall zwischen (R)CT-Komplettierung und Operation, auf postoperative Komplikationen, Tumorresponse sowie Langzeitüberleben. Zwischen 2006 und 2013 wurden 106 Patienten mit Adeno- und Plattenepithelkarzinom des Ösophagus eingeschlossen, die eine n(R)CT mit nachfolgender Resektion erhielten. Basierend auf der medianen Dauer der Therapiepause wurden zwei Gruppen [Gruppe A ≤ 40 Tage (n = 54), Gruppe B > 40 Tage (n = 52)] unterschieden und bezüglich der demographischen Daten, präoperativen Risikoscores, postoperativen Komplikationen, des Therapieansprechens und Langzeitüberlebens verglichen. Beide Gruppen waren hinsichtlich der Demographie, des präoperativen Gesundheitszustands, der Komplikationen und des Outcomes vergleichbar. Ein Trend bestand jedoch zu einem erhöhten präoperativ erfassten Mortalitätsrisiko nach dem O-POSSUM-Score bei kurzer Therapiepause (p = 0,064) sowie zu einem höheren Anteil an kompletten Respondern bei Patienten mit längerer Therapiepause (p = 0,097). Im Hinblick auf die perioperative Morbidität und Mortalität zeigte die Studie keine Überlegenheit einer längeren oder kürzeren Therapiepause nach n(R)CT. Allerdings fanden sich mehr Patienten mit kompletter Tumorresponse in der Gruppe mit längerer Therapiepause. Dies blieb allerdings ohne Einfluss auf das Langzeitüberleben oder die Rezidivrate. Neoadjuvant radiochemotherapy [n(R)CT] has become the standard of care in the multimodal therapy concept for patients with locally advanced esophageal cancer; however, optimal timing of surgery is not clearly defined. The study analyzed whether the length of the interval between completion of n(R)CT and surgery can affect the postoperative outcome, tumor response and long-term survival. A total of 106 patients with adenocarcinoma and squamous cell carcinoma of the esophagus, treated between 2006 and 2013, were included in this study. On the basis of the median time interval to surgery, patients were divided into two groups [group A ≤ 40 days (n = 54) and group B > 40 days (n = 52)] and compared concerning demographic data, preoperative risk scores, morbidity, outcome, tumor response and long-term survival. The groups were comparable in terms of demographics, preoperative condition of the patients, complications and outcome; however, group A showed a trend towards a higher mortality risk as preoperatively assessed by the physiological and operative severity score for the enumeration of mortality and morbidity in esophagogastric surgery patients (O-POSSUM) (p = 0.064) and group B showed a trend towards a higher rate of complete responders (p = 0.097). Concerning perioperative morbidity and mortality, delayed surgery after n(R)CT showed no benefit for the patient’s outcome; however, the rate of complete tumor response was higher in patients with a time interval of more than 40 days, although this did not influence long-term survival or recurrence rates.
- 8 February 2015
- Published by Springer Nature in Der Chirurg
- Vol. 86 (9) , 874-880
Therapiepause in der multimodalen Behandlung des Ösophaguskarzinoms
Die neoadjuvante (Radio-)Chemotherapie [n(R)CT] ist fester Bestandteil des multimodalen Therapiekonzepts beim fortgeschrittenen Ösophaguskarzinom, wobei der optimale Operationszeitpunkt nach komplettierter n(R)CT nicht eindeutig definiert ist. Die Studie untersucht die Auswirkung der Therapiepause, definiert als Intervall zwischen (R)CT-Komplettierung und Operation, auf postoperative Komplikationen, Tumorresponse sowie Langzeitüberleben. Zwischen 2006 und 2013 wurden 106 Patienten mit Adeno- und Plattenepithelkarzinom des Ösophagus eingeschlossen, die eine n(R)CT mit nachfolgender Resektion erhielten. Basierend auf der medianen Dauer der Therapiepause wurden zwei Gruppen [Gruppe A ≤ 40 Tage (n = 54), Gruppe B > 40 Tage (n = 52)] unterschieden und bezüglich der demographischen Daten, präoperativen Risikoscores, postoperativen Komplikationen, des Therapieansprechens und Langzeitüberlebens verglichen. Beide Gruppen waren hinsichtlich der Demographie, des präoperativen Gesundheitszustands, der Komplikationen und des Outcomes vergleichbar. Ein Trend bestand jedoch zu einem erhöhten präoperativ erfassten Mortalitätsrisiko nach dem O-POSSUM-Score bei kurzer Therapiepause (p = 0,064) sowie zu einem höheren Anteil an kompletten Respondern bei Patienten mit längerer Therapiepause (p = 0,097). Im Hinblick auf die perioperative Morbidität und Mortalität zeigte die Studie keine Überlegenheit einer längeren oder kürzeren Therapiepause nach n(R)CT. Allerdings fanden sich mehr Patienten mit kompletter Tumorresponse in der Gruppe mit längerer Therapiepause. Dies blieb allerdings ohne Einfluss auf das Langzeitüberleben oder die Rezidivrate. Neoadjuvant radiochemotherapy [n(R)CT] has become the standard of care in the multimodal therapy concept for patients with locally advanced esophageal cancer; however, optimal timing of surgery is not clearly defined. The study analyzed whether the length of the interval between completion of n(R)CT and surgery can affect the postoperative outcome, tumor response and long-term survival. A total of 106 patients with adenocarcinoma and squamous cell carcinoma of the esophagus, treated between 2006 and 2013, were included in this study. On the basis of the median time interval to surgery, patients were divided into two groups [group A ≤ 40 days (n = 54) and group B > 40 days (n = 52)] and compared concerning demographic data, preoperative risk scores, morbidity, outcome, tumor response and long-term survival. The groups were comparable in terms of demographics, preoperative condition of the patients, complications and outcome; however, group A showed a trend towards a higher mortality risk as preoperatively assessed by the physiological and operative severity score for the enumeration of mortality and morbidity in esophagogastric surgery patients (O-POSSUM) (p = 0.064) and group B showed a trend towards a higher rate of complete responders (p = 0.097). Concerning perioperative morbidity and mortality, delayed surgery after n(R)CT showed no benefit for the patient’s outcome; however, the rate of complete tumor response was higher in patients with a time interval of more than 40 days, although this did not influence long-term survival or recurrence rates.
- 29 January 2015
- Published by Wiley in World Journal of Surgery
- Vol. 39 (5) , 1322-1324
Postoperative Complications Do Not Affect Long‐Term Outcome in Esophageal Cancer Patients: Reply
- 29 January 2015
- Published by Wiley in World Journal of Surgery
- Vol. 39 (5) , 1322-1324
Postoperative Complications Do Not Affect Long‐Term Outcome in Esophageal Cancer Patients: Reply
- 27 August 2014
- Published by Portland Press Ltd. in Clinical Science
- Vol. 128 (1) , 1-15
Circulating microRNAs: emerging biomarkers for diagnosis and prognosis in patients with gastrointestinal cancers
To identify novel non-invasive biomarkers for improved detection, risk assessment and prognostic evaluation of cancer, expression profiles of circulating microRNAs are currently under evaluation. Circulating microRNAs are highly promising candidates in this context, as they present some key characteristics for cancer biomarkers: they are tissue-specific with reproducible expression and consistency among individuals from the same species, they are potentially derived directly from the tumour and therefore might correlate with tumour progression and recurrence, and they are bound to proteins or contained in subcellular particles, such as microvesicles or exosomes, making them highly stable and resistant to degradation. The present review highlights the origin of circulating microRNAs, their stability in blood samples, and techniques to isolate exosomal microRNAs, and then addresses the current evidence supporting potential clinical applications of circulating miRNAs for diagnostic and prognostic purposes.
- 27 August 2014
- Published by Portland Press Ltd. in Clinical Science
- Vol. 128 (1) , 1-15
Circulating microRNAs: emerging biomarkers for diagnosis and prognosis in patients with gastrointestinal cancers
To identify novel non-invasive biomarkers for improved detection, risk assessment and prognostic evaluation of cancer, expression profiles of circulating microRNAs are currently under evaluation. Circulating microRNAs are highly promising candidates in this context, as they present some key characteristics for cancer biomarkers: they are tissue-specific with reproducible expression and consistency among individuals from the same species, they are potentially derived directly from the tumour and therefore might correlate with tumour progression and recurrence, and they are bound to proteins or contained in subcellular particles, such as microvesicles or exosomes, making them highly stable and resistant to degradation. The present review highlights the origin of circulating microRNAs, their stability in blood samples, and techniques to isolate exosomal microRNAs, and then addresses the current evidence supporting potential clinical applications of circulating miRNAs for diagnostic and prognostic purposes.
- 28 May 2014
- Published by Wiley in World Journal of Surgery
- Vol. 38 (10) , 2652-2661
Postoperative Complications Do Not Affect Long‐Term Outcome in Esophageal Cancer Patients
Background: As esophagectomy is associated with a considerable complication rate, the aim of this study was to assess the impact of postoperative complications and neoadjuvant treatment on long‐term outcome of adenocarcinoma (EAC) and squamous cell carcinoma (SCC) patients.Methods: Altogether, 134 patients undergoing transthoracic esophagectomy between 2005 and 2010 with intrathoracic stapler anastomosis were included in the study. Postoperative complications were allocated into three main categories: overall complications, acute anastomotic insufficiency, and pulmonary complications. Data were collected prospectively and reviewed retrospectively for the purpose of this study.Results: SCC patients suffered significantly more often from overall and pulmonary complications (SCC vs. EAC: overall complications 67 vs. 45 %, p = 0.044; pulmonary complications 56 vs. 34 %, p = 0.049). The anastomotic insufficiency rates did not differ significantly (SCC 11%, EAC 15%, p = 0.69). Long‐term survival of EAC and SCC patients was not affected by perioperative (overall/pulmonary) complications or by the occurrence of anastomotic insufficiency. Also, neoadjuvant treatment did not influence the incidence of complications or long‐term survival.Conclusions: This is the first time the patient population of a center experienced with esophageal cancer surgery was assessed for the occurrence of general and esophageal cancer surgery‐specific perioperative complications. Our results indicated that these complications did not affect long‐term survival of EAC and SCC patients. Our data support the hypothesis that neoadjuvant treatment might not affect the incidence of perioperative complications or long‐term survival after treatment of these tumor subtypes.
- 28 May 2014
- Published by Wiley in World Journal of Surgery
- Vol. 38 (10) , 2652-2661
Postoperative Complications Do Not Affect Long‐Term Outcome in Esophageal Cancer Patients
Background: As esophagectomy is associated with a considerable complication rate, the aim of this study was to assess the impact of postoperative complications and neoadjuvant treatment on long‐term outcome of adenocarcinoma (EAC) and squamous cell carcinoma (SCC) patients.Methods: Altogether, 134 patients undergoing transthoracic esophagectomy between 2005 and 2010 with intrathoracic stapler anastomosis were included in the study. Postoperative complications were allocated into three main categories: overall complications, acute anastomotic insufficiency, and pulmonary complications. Data were collected prospectively and reviewed retrospectively for the purpose of this study.Results: SCC patients suffered significantly more often from overall and pulmonary complications (SCC vs. EAC: overall complications 67 vs. 45 %, p = 0.044; pulmonary complications 56 vs. 34 %, p = 0.049). The anastomotic insufficiency rates did not differ significantly (SCC 11%, EAC 15%, p = 0.69). Long‐term survival of EAC and SCC patients was not affected by perioperative (overall/pulmonary) complications or by the occurrence of anastomotic insufficiency. Also, neoadjuvant treatment did not influence the incidence of complications or long‐term survival.Conclusions: This is the first time the patient population of a center experienced with esophageal cancer surgery was assessed for the occurrence of general and esophageal cancer surgery‐specific perioperative complications. Our results indicated that these complications did not affect long‐term survival of EAC and SCC patients. Our data support the hypothesis that neoadjuvant treatment might not affect the incidence of perioperative complications or long‐term survival after treatment of these tumor subtypes.
- 4 April 2014
- Published by Springer Nature in Der Onkologe
- Vol. 20 (5) , 490-491
Zirkulierende micro-RNA als Responsemarker beim Ösophaguskarzinom
- 4 April 2014
- Published by Springer Nature in Der Onkologe
- Vol. 20 (5) , 490-491
Zirkulierende micro-RNA als Responsemarker beim Ösophaguskarzinom
- Open Access
- 1 January 2014
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 20 (38) , 13658-13666
MicroRNAs: Promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential
Gastric cancer (GC) is the fourth most common cancer worldwide and ranks second in global cancer mortality statistics. Perioperative chemotherapy plays an important role in the management and treatment of advanced stage disease. However, response to chemotherapy varies widely, with some patients presenting no or only minor response to treatment. Hence, chemotherapy resistance is a major clinical problem that impacts on outcome. Unfortunately, to date there are no reliable biomarkers available that predict response to chemotherapy before the start of the treatment, or that allow modification of chemotherapy resistance. MicroRNAs (miRNAs) could provide an answer to this problem. miRNAs are involved in the initiation and progression of a variety of cancer types, and there is evidence that miRNAs impact on resistance towards chemotherapeutic drugs as well. This current review aims to provide an overview about the potential clinical applicability of miRNAs as biomarkers for chemoresistance in GC. The authors focus in this context on the potential of miRNAs to predict sensitivity towards different chemotherapeutics, and on the potential of miRNAs to modulate sensitivity and resistance towards chemotherapy in GC.
- 1 January 2014
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 20 (38) , 13658-13666
Open AccessMicroRNAs: Promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential
Gastric cancer (GC) is the fourth most common cancer worldwide and ranks second in global cancer mortality statistics. Perioperative chemotherapy plays an important role in the management and treatment of advanced stage disease. However, response to chemotherapy varies widely, with some patients presenting no or only minor response to treatment. Hence, chemotherapy resistance is a major clinical problem that impacts on outcome. Unfortunately, to date there are no reliable biomarkers available that predict response to chemotherapy before the start of the treatment, or that allow modification of chemotherapy resistance. MicroRNAs (miRNAs) could provide an answer to this problem. miRNAs are involved in the initiation and progression of a variety of cancer types, and there is evidence that miRNAs impact on resistance towards chemotherapeutic drugs as well. This current review aims to provide an overview about the potential clinical applicability of miRNAs as biomarkers for chemoresistance in GC. The authors focus in this context on the potential of miRNAs to predict sensitivity towards different chemotherapeutics, and on the potential of miRNAs to modulate sensitivity and resistance towards chemotherapy in GC.